Prostate cancer has a highly tumor-restricted prostate-specific membrane antigen (PSMA) and may be the ideal solid-organ malignancy for treatment with radioimmunotherapy.
Encouraging results using lutetium-177-labeled anti-PSMA monoclonal antibody J591 from a phase II study by Tawaga and colleagues support the continued clinical and preclinical development of radioimmunotherapy for solid tumors.
Written by:
Simone CB 2nd, Hahn SM. Are you the author?
Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
Reference: Clin Cancer Res. 2013 Sep 5. Epub ahead of print.
doi: 10.1158/1078-0432.CCR-13-1540
PubMed Abstract
PMID: 23926229
UroToday.com Prostate Cancer Immunotherapy Section
